Patents Assigned to Advanced Accelerator Applications
-
Patent number: 11904027Abstract: The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.Type: GrantFiled: March 23, 2020Date of Patent: February 20, 2024Assignee: Advanced Accelerator ApplicationsInventors: Francesco de Palo, Lorenza Fugazza, Donato Barbato, Maurizio Mariani, Daniela Chicco, Giovanni Tesoriere, Clementina Brambati
-
Publication number: 20240050597Abstract: The present disclosure relates to ?v?3 and/or ?v?5 integrins antagonist radiopharmaceuticals and their use in a theragnostic approach for selection and therapy of human subjects with tumors overexpressing ?v?3 and/or ?v?5 integrins. In particular, the present disclosure relates to a pharmaceutical composition of ?v 177Lu radiolabeled ?v?3 and/or ?v?5 integrins antagonist, for use in treating tumors overexpressing ?v?3 and/or ?v?5 integrins in a human subject eligible for said treatment, wherein said subject has been selected for the treatment by PET/CT or PET/MRI or SPECT/CT or SPECT/MRI imaging with the same ?v?3 and/or ?v?5 integrins antagonist but with 68-Ga as radiometal for use as imaging agent.Type: ApplicationFiled: December 20, 2021Publication date: February 15, 2024Applicants: ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA, ADVANCED ACCELERATOR APPLICATIONS (ITALY) SRL, NOVARTIS AGInventors: Valeria MUZIO, Antje WEGENER, John Scott CAMERON, Francesco DE CARLI, Paola BARDINI, Alessandro MAGRI, Mattia ROSSETTO, Daniela BARENGO
-
Patent number: 11430580Abstract: A neutron activator includes a neutron source and a reflector-moderator. The neutron source has a housing extending along a longitudinal axis (B). A metallic target as part of the neutron source is provided to produce neutrons through the interaction with a proton beam, the metallic target having a plurality of plates arranged transversally with respect to the longitudinal axis (B). The neutron source also includes a cooling circuit to cool the metallic target. The reflector-moderator has an activation area configured to accommodate the neutron source and the material to be activated.Type: GrantFiled: July 5, 2019Date of Patent: August 30, 2022Assignee: ADVANCED ACCELERATOR APPLICATIONSInventors: Luca Maciocco, Ilyes Zahi
-
Patent number: 11257603Abstract: A neutron activator for neutron activation of a material, the neutron activator being configured to produce neutrons from an interaction with a proton beam (7), the neutron activator comprising: a neutron source comprising a metallic target (1), and a Beryllium first reflector-moderator (4) peripheral to the neutron source and comprising a neutron activation area (10) configured to accommodate the neutron source and the material to be activated, the neutron activation area (10) of the first reflector-moderator (4) comprising a bore configured to accommodate the neutron source.Type: GrantFiled: April 24, 2018Date of Patent: February 22, 2022Assignee: ADVANCED ACCELERATOR APPLICATIONSInventors: Luca Maciocco, Stefano Buono
-
Publication number: 20220041649Abstract: The present disclosure relates to the synthesis of radionuclide complex solutions, in particular for their use in the commercial production of radioactive drug substances, for diagnostic and/or therapeutic purposes. In particular, the synthesis method comprises the following steps in the following order: a. providing a radionuclide precursor solution into a first vial, b. transferring the radionuclide precursor solution into a reactor, c. providing a reaction buffer solution into said first vial containing residual radionuclide precursor solution, d. transferring the buffer reaction solution and residual radionuclide precursor solution from said first vial into the reactor, e. transferring a peptide solution comprising the somatostatin receptor binding peptide linked to a chelating agent, into the reactor, f. reacting the somatostatin receptor binding peptide linked to a chelating agent with said radionuclide in the reactor to obtain the radionuclide complex, g. recovering said radionuclide complex.Type: ApplicationFiled: May 27, 2021Publication date: February 10, 2022Applicant: Advanced Accelerator Applications (Italy) S.R.L.Inventors: Lorenza Fugazza, Francesco De Palo, Donato Barbato, Maurizio F. Mariani, Giovanni Tesoriere, Clementina Brambati
-
Publication number: 20220031872Abstract: It is described a composition comprising lyophilized rhAnnexin V-128 suitable for the preparation of 99mTc-rhAnnexin V-128 formulations suitable for intravenous administration.Type: ApplicationFiled: August 10, 2021Publication date: February 3, 2022Applicant: Advanced Accelerator Applications International S.A.Inventors: Lorenza Fugazza, Maurizio Franco Mariani, Francesca Orlandi, Daniela Chicco, Donato Barbato
-
Publication number: 20220008566Abstract: The present disclosure relates to gastrin-releasing peptide receptor (GRPR) targeting radiopharmaceuticals and uses thereof. In particular, the present disclosure relates to a pharmaceutical composition comprising radiolabeled GRPR-antagonist and a surfactant. The present disclosure also relates to radiolabeled GRPR-antagonist for use in treating or preventing a cancer.Type: ApplicationFiled: October 11, 2019Publication date: January 13, 2022Applicant: Advanced Accelerator Applications International SAInventors: Francesca Orlandi, Lorenza Fugazza, Donato Barbato, Mattia Tedesco, Lorenzo Sacchetti
-
Publication number: 20220008568Abstract: The present invention relates to probes for use in the detection, imaging, diagnosis, targeting, treatment, etc. of cancers expressing the gastrin releasing peptide receptor (GRPR). For example, such probes may be molecules conjugated to detectable labels which are preferably moieties suitable for detection by gamma imaging and SPECT or by positron emission tomography (PET) or magnetic resonance imaging (MRI) or fluorescence spectroscopy or optical imaging methods.Type: ApplicationFiled: July 23, 2021Publication date: January 13, 2022Applicant: Advanced Accelerator Applications International SAInventors: Theodosia Maina-Nock, Berthold Artur Nock, Marion de Jong Hendriks
-
Publication number: 20210346528Abstract: The present invention relates to probes for use in the detection, imaging, diagnosis, targeting, treatment, etc. of cancers expressing the gastrin releasing peptide receptor (GRPR). For example, such probes may be molecules conjugated to detectable labels which are preferably moieties suitable for detection by gamma imaging and SPECT or by positron emission tomography (PET) or magnetic resonance imaging (MRI) or fluorescence spectroscopy or optical imaging methods.Type: ApplicationFiled: July 23, 2021Publication date: November 11, 2021Applicant: Advanced Accelerator Applications International SAInventors: Theodosia Maina-Nock, Berthold Artur Nock, Marion de Jong Hendriks
-
Publication number: 20210346527Abstract: The present invention relates to combination therapies of radiolabelled somatostatin receptor binding compounds with PARR inhibitors.Type: ApplicationFiled: September 24, 2019Publication date: November 11, 2021Applicant: Advanced Accelerator Applications (Italy) SRLInventors: Maurizio F. Mariani, Francesca Orlandi, Daniela Chicco, Valeria Muzio, Carmelina Angotti
-
Publication number: 20210346529Abstract: The present invention relates to probes for use in the detection, imaging, diagnosis, targeting, treatment, etc. of cancers expressing the gastrin releasing peptide receptor (GRPR). For example, such probes may be molecules conjugated to detectable labels which are preferably moieties suitable for detection by gamma imaging and SPECT or by positron emission tomography (PET) or magnetic resonance imaging (MRI) or fluorescence spectroscopy or optical imaging methods.Type: ApplicationFiled: July 23, 2021Publication date: November 11, 2021Applicant: Advanced Accelerator Applications International SAInventors: Theodosia Maina-Nock, Berthold Artur Nock, Marion de Jong Hendriks
-
Publication number: 20210316019Abstract: The present disclosure relates to the synthesis of radionuclide complex solutions, in particular for their use in the commercial production of radioactive drug substances, for diagnostic and/or therapeutic purposes. In particular, the synthesis method comprises the following steps in the following order: a. providing a radionuclide precursor solution into a first vial, b. transferring the radionuclide precursor solution into a reactor, c. providing a reaction buffer solution into said first vial containing residual radionuclide precursor solution, d. transferring the buffer reaction solution and residual radionuclide precursor solution from said first vial into the reactor, e. transferring a peptide solution comprising the somatostatin receptor binding peptide linked to a chelating agent, into the reactor, f. reacting the somatostatin receptor binding peptide linked to a chelating agent with said radionuclide in the reactor to obtain the radionuclide complex, g. recovering said radionuclide complex.Type: ApplicationFiled: October 31, 2019Publication date: October 14, 2021Applicant: Advanced Accelerator Applications (Italy) SRLInventors: Lorenza Fugazza, Francesco de Palo, Donato Barbato, Maurizio F. Mariani, Giovanni Tesoriere, Clementina Brambati
-
Patent number: 11083805Abstract: The present invention relates to probes for use in the detection, imaging, diagnosis, targeting, treatment, etc. of cancers expressing the gastrin releasing peptide receptor (GRPR). For example, such probes may be molecules conjugated to detectable labels which are preferably moieties suitable for detection by gamma imaging and SPECT or by positron emission tomography (PET) or magnetic resonance imaging (MRI) or fluorescence spectroscopy or optical imaging methods.Type: GrantFiled: September 24, 2019Date of Patent: August 10, 2021Assignee: Advanced Accelerator Applications International SAInventors: Theodosia Maina-Nock, Berthold Artur Nock, Marion de Jong Hendriks
-
Publication number: 20200131224Abstract: The present disclosure relates to the synthesis of radionuclide complex solutions, in particular for their use in the commercial production of radioactive drug substances, for diagnostic and/or therapeutic purposes. In particular, the synthesis method comprises the following steps in the following order: a. providing a radionuclide precursor solution into a first vial, b. transferring the radionuclide precursor solution into a reactor, c. providing a reaction buffer solution into said first vial containing residual radionuclide precursor solution, d. transferring the buffer reaction solution and residual radionuclide precursor solution from said first vial into the reactor, e. transferring a peptide solution comprising the somatostatin receptor binding peptide linked to a chelating agent, into the reactor, f. reacting the somatostatin receptor binding peptide linked to a chelating agent with said radionuclide in the reactor to obtain the radionuclide complex, g. recovering said radionuclide complex.Type: ApplicationFiled: April 24, 2019Publication date: April 30, 2020Applicant: Advanced Accelerator Applications (Italy) S.R.L.Inventors: Lorenza Fugazza, Francesco De Palo, Donato Barbato, Maurizio F. Mariani, Giovanni Tesoriere, Clementina Brambati
-
Patent number: 10596276Abstract: The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.Type: GrantFiled: October 30, 2018Date of Patent: March 24, 2020Assignee: ADVANCED ACCELERATOR APPLICATIONS (ITALY) S.R.L.Inventors: Francesco de Palo, Lorenza Fugazza, Donato Barbato, Maurizio Mariani, Daniela Chicco, Giovanni Tesoriere, Clementina Brambati
-
Patent number: 10596278Abstract: The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.Type: GrantFiled: October 30, 2018Date of Patent: March 24, 2020Assignee: ADVANCED ACCELERATOR APPLICATIONS (ITALY) S.R.L.Inventors: Francesco de Palo, Lorenza Fugazza, Donato Barbato, Maurizio Mariani, Daniela Chicco, Giovanni Tesoriere, Clementina Brambati
-
Publication number: 20200038526Abstract: It is described a composition comprising lyophilized rhAnnexin V-128 suitable for the preparation of 99mTc-rhAnnexin V-128 formulations suitable for intravenous administration.Type: ApplicationFiled: October 11, 2017Publication date: February 6, 2020Applicant: Advanced Accelerator Applications International S.A.Inventors: Lorenza Fugazza, Maurizio Franco Mariani, Francesca Orlandi, Daniela Chicco, Donato Barbato
-
Publication number: 20190119316Abstract: Nucleophile-reactive sulfonated compounds used as precursors to (radio)labelled (bio) molecules are produced by pre-introduction of a nucleophilic compound R* through an unusual nucleophile-induced ring-opening reaction of the sultone moiety of the precursor. The precursors and compounds conformconform.torespective formulae (Ip) and (I): Also disclosed are methods for producing these precursors and compounds, as well as for conjugation of these compounds with (bio)molecules, and to the drugs obtained by this method.Type: ApplicationFiled: December 21, 2018Publication date: April 25, 2019Applicant: Advanced Accelerator Applications SAInventors: Thomas PRIEM, Cedric BOUTEILLER, Davide CAMPORESE, Anthony ROMIEU, Pierre-Yves RENARD
-
Patent number: 10196421Abstract: Nucleophile-reactive sulfonated compounds used as precursors to (radio)labelled (bio)molecules are produced by pre-introduction of a nucleophilic compound R* through an unusual nucleophile-induced ring-opening reaction of the sultone moiety of the precursor. The precursors and compounds conform to respective formulae (Ip) and (I): Also disclosed are methods for producing these precursors and compounds, as well as for conjugation of these compounds with (bio)molecules, and to the drugs obtained by this method.Type: GrantFiled: February 16, 2017Date of Patent: February 5, 2019Assignee: Advanced Accelerator Applications SAInventors: Thomas Priem, Cedric Bouteiller, Davide Camporese, Anthony Romieu, Pierre-Yves Renard
-
Patent number: 9907868Abstract: A process for the preparation of complexes containing 68Ga wherein a buffer formic acid/formate in the presence of compounds capable to sequester metal cations is used in the complexation reaction.Type: GrantFiled: May 24, 2016Date of Patent: March 6, 2018Assignee: Advanced Accelerator Applications International S.A.Inventors: Lorenza Fugazza, Maria Azzurra Filannino, Maurizio Franco Mariani